Evidence map›Paper›PMID 29128901›Full record

ArticleImmunologic research2018

FGL2 knockdown improves heart function through regulation of TLR9 signaling in the experimental autoimmune myocarditis rats.

Zhenzhong Zheng, Longhui Yu, Yujing Wu, Hao Wu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Zhenzhong ZhengDepartment of Cardiology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, People's Republic of China. greateful@163.com.ORCID 0000-0001-9239-3996
Longhui YuDepartment of Cardiology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, People's Republic of China.
Yujing WuDepartment of Cardiology, The First Affiliated Hospital of Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, People's Republic of China.
Hao WuVascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, 02115, USA. hao.wu3@childrens.harvard.edu.
Nanchang University · CNBoston Children's Hospital · US

Funding

American Heart Association-American Stroke Association 17SDG33410868
6 · The paper itself

Abstract

Fibrinogen-like protein 2 (FGL2) is an important immune regulator of both innate and adaptive response. It is present on the surface of macrophages and endothelial cells, and can be constitutively secreted by CD4

Indexed as

AnimalsAutoimmune DiseasesCardiac MyosinsFibrinogenGene Expression RegulationHumansInflammationInterferon-alphaLentivirusMaleModels, AnimalMyocarditisMyocardiumNF-kappa BRatsRats, Inbred LewCardiac MyosinsFibrinogenfibrinogen-like protein 2, ratInterferon-alphaNF-kappa BRNA, Small InterferingTlr9 protein, ratToll-Like Receptor 9Experimental autoimmune myocarditisFibrinogen-like protein 2Toll receptor 9

Identifiers

PMID29128901
PMCPMC11025570
OpenAlexW2767763651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.